Search results
Results from the WOW.Com Content Network
Laboratory testing for antibody to CMV can be performed to determine if a woman has already had CMV infection. Recovery of CMV from the cervix or urine of women at or before the time of delivery does not warrant a cesarean section. The demonstrated benefits of breast-feeding outweigh the minimal risk of acquiring CMV from the breast-feeding mother.
People whose condition was caused by a recent viral infection should make a full recovery without treatment in a few months. Fine motor skills, such as handwriting, typically have to be practised in order to restore them to their former ability. In more serious cases, strokes, bleeding or infections may sometimes cause permanent symptoms.
CMV placentitis. When physical examination of the newborn shows signs of a vertically transmitted infection, the examiner may test blood, urine, and spinal fluid for evidence of the infections listed above. Diagnosis can be confirmed by culture of one of the specific pathogens or by increased levels of IgM against the pathogen. [citation needed]
Cytomegalovirus (CMV) (from cyto-'cell' via Greek κύτος kútos - 'container' + μέγας mégas 'big, megalo-' + -virus via Latin vīrus 'poison') is a genus of viruses in the order Herpesvirales, in the family Herpesviridae, [3] in the subfamily Betaherpesvirinae. Humans and other primates serve as natural hosts.
Human CMV is also linked to age-associated T cell dysfunction, contributing to immunosenescence. [50] In persons infected with CMV about 10% of memory T cells are CMV-specific, but these may expand to as much as 30% in the elderly, [51] 50% or more of CD8 + memory T-cells. [52]
Maribavir, sold under the brand name Livtencity, is an antiviral medication that is used to treat post-transplant cytomegalovirus (CMV). [8] [9] Maribavir is a cytomegalovirus pUL97 kinase inhibitor that works by preventing the activity of human cytomegalovirus enzyme pUL97, thus blocking virus replication.
Cytomegalic inclusion body disease (CIBD) also known as cytomegalic inclusion disease (CID) is a series of signs and symptoms caused by cytomegalovirus infection, toxoplasmosis or other rare infections such as herpes or rubella viruses.
A phase 2 study of a recombinant gB protein subunit CMV-vaccine "gB/MF59" was published in 2009 and indicated an efficacy of 50% in seronegative women of childbearing-age thus the protection provided was limited and a number of subjects contracted CMV infection despite the vaccination. In one case congenital CMV was encountered.